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Approximately30–50%ofthe>30millionHIV-infectedsub-
jects develop neurological complications ranging from mild
symptoms to dementia. HIV does not infect neurons, and the
molecular mechanisms behind HIV-associated neurocognitive
decline are not understood. There are several hypotheses to
explain the development of dementia in HIV
 individuals,
including neuroinflammation mediated by infected microglia
and neuronal toxicity by HIV proteins. A key protein associated
with the neurological complications of HIV, gp120, forms part
of the viral envelope and can be found in the CSF of infected
individuals. HIV-1-gp120 interacts with several receptors
including CD4, CCR5, CXCR4, and nicotinic acetylcholine
receptors(nAChRs).However,theroleofnAChRsinHIV-asso-
ciated neurocognitive disorder has not been investigated. We
studiedtheeffectsofgp120IIIBontheexpressionandfunctionof
the nicotinic receptor 7( 7-nAChR). Our results show that
gp120, through activation of the CXCR4 chemokine receptor,
induces a functional up-regulation of 7-nAChRs. Because
7-nAChRs have a high permeability to Ca
2, we performed
TUNELstainingtoinvestigatetheeffectsofreceptorup-regula-
tiononcellviability.Ourdatarevealedanincreaseincelldeath,
which was blocked by the selective antagonist -bungarotoxin.
The in vitro data are supported by RT-PCR and Western blot
analysis, confirming a remarkable up-regulation of the
7-nAChR in gp120-transgenic mice brains. Specifically,
7-nAChR up-regulation is observed in mouse striatum, a
region severely affected in HIV
 patients. In summary, CXCR4
activation induces up-regulation of 7-nAChR, causing cell
death, suggesting that 7-nAChR is a previously unrecognized
contributor to the neurotoxicity associated with HIV infection.
More than 30 million people are infected with HIV world-
wide (1). In addition to the health problems caused by immu-
nosuppression, HIV infection causes HIV-associated neuro-
cognitive disorder (HAND),
4 a neurodegenerative disease that
leads to severe cognitive, motor, and behavioral disturbances.
Before the introduction of highly active antiretroviral therapy
(HAART),30–50%ofHIV-infectedpatientsdevelopedHAND;
aftertheincorporationofHAARTaspartofHIVtreatment,the
incidence decreased to 10% (2–5). Nevertheless, in associa-
tion with the existence of HAART treatment, which prolongs
the life of HIV-infected individuals, there has been an increase
to 30% in the number of individuals who develop a milder
formofneurocognitivedysfunctionknownasminorcognitive-
motor disorder, which is characterized by neurological deficits
that do not interfere with everyday functioning (6). Therefore,
despite the reduction in HAND incidence, its prevalence is
expected to increase due the improved care of HIV-infected
patients. When evaluating the alterations in the incidence of
HANDasaresultofHAART,itisimportanttoconsiderthatof
the 30 million HIV-infected individuals worldwide, only 2
million have access to HAART (1). In addition, HIV infection
continues to be the most common cause of dementia in young
adults in the United States (7, 8). This suggests that HAND will
continue to be an important health care problem in the United
States and worldwide.
The presence of neurological symptoms in HIV-infected
patientsisaninterestingfinding,consideringthatHIVdoesnot
infect neurons directly. The molecular mechanisms by which
HIV infection leads to neurocognitive decline are not fully
understood, but several hypotheses have emerged to explain
the development of neurocognitive impairment in HIV
 indi-
viduals. Two potential mechanisms by which HIV infection
could interfere with normal brain functioning are (i) chemo-
kine-inducedneuroinflammationmediatedbyinfectedmacro-
phages/microglia and (ii) direct neuronal toxicity induced by
soluble HIV proteins (9). HIV-1-gp120, a glycoprotein that
forms part of the envelope of HIV-1 particles, can be found in
the cerebrospinal fluid of HIV
 individuals, and it has been
shown to have neurotoxic effects in cell cultures (9–13). HIV-
1-gp120 interacts with several receptors found in the central
nervous system (CNS), including CD4, CCR5, and CXCR4, as
well as nicotinic acetylcholine receptors (nAChRs) (14–16).
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Supplemental Material can be found at:Several lines of evidence suggest the potential involvement of
the nicotinic acetylcholine receptor 7-nAChR in HIV neuro-
pathology (17–19); however, the role that nAChRs may play in
the development of HAND has not been investigated.
For HIV-1 to infect cells, it must bind the CD4 receptor and
either the CCR5 or CXCR4 co-receptor. Interestingly, during
the course of infection, HIV-1 evolves from an M-tropic
(CCR5-dependent) variant that primarily infects macrophages
toaT-tropic(CXCR4-dependent)variantthatprimarilyinfects
T cells (15, 20). The increase in HIV particles with tropism for
CXCR4 receptor correlates with the development of HAND
(20, 21). Studies have shown that gp120 not only binds to
CXCR4, but also activates its signaling pathway (22). CXCR4
activation by stromal cell-derived growth factor (SDF-1), the
endogenous agonist of CXCR4, has been shown to rapidly up-
regulate the early growth response gene 1 (Egr-1), a transcrip-
tionfactorknowntodrivetheexpressionofthe7-nAChR(23,
24).Furthermore,ithasbeenshownthatSDF-1issecretedby
astrocytes during inflammation and is increased in response to
macrophageactivationbyHIVinfection(25).Consequently,we
designed experiments to study the effects of gp120 on the
expressionandfunctionof7-nAChRsinSH-SY5Yneuroblas-
toma cells, which endogenously express 7-nAChRs and
CXCR4 receptors (26). Our results show that CXCR4 activa-
tion, by gp120 or SDF-1, leads to an increase in 7-nAChR
activity that can culminate in cell death. In addition, Western
blotting and quantitative RT-PCR analysis confirm up-regula-
tion of 7-nAChR in transgenic mice expressing the HIV-
gp120 gene.
MATERIALS AND METHODS
Fluorescent -Bungarotoxin (Bgtx) Binding—SH-SY5Y cells
weregrownin4-welltissuecultureslides(NalgeNuncInterna-
tional, Rochester, NY). Cell culture medium was removed, the
cells were washed with phosphate-buffered saline (PBS), fixed
by incubation with 4% paraformaldehyde for 10 min followed
byincubationwith1%bovineserumalbumin(BSA)for10min.
ThecellswerewashedwithPBSandthenincubatedwithAlexa
Fluor 488-conjugated -bgtx (Invitrogen) 1:50 for1ha troom
temperature.CellswerethenwashedthreetimeswithPBS,and
coverslips were mounted with 90% glycerol and analyzed with
an Axiovert 200M confocal microscope.
Electrophysiology—Wholecellcurrentsweremeasuredinthe
whole cell configuration of the patch clamp technique using an
Axopatch 200B amplifier (Axon Instruments, Foster City, CA).
The bath solution contained 140 mM NaCl, 4 mM KCl, 2 mM
CaCl2,1m MMgCl2,5m MHEPES,10mMglucose,pH7.4,280
mosmol/kg. The pipette solution contained 145 mM KCl, 6 mM
MgCl2,7.2mMK2HPO4,2.8mMKH2PO4,5m MEDTA,pH7.4,
270 mosmol/kg. Pipettes were pulled from thick wall boro-
silicateglass(WorldPrecisionInstruments,Sarasota,FL)witha
multistage P-87 Flaming-Brown micropipette puller (Sutter
Instruments, San Rafael, CA) and fire-polished. Pipette resis-
tance was 2–4 megohms, and a 1–2% agar bridge with compo-
sition similar to the bath solution was utilized as the reference
electrode. Chemicals were purchased from Sigma. Whole cell
current traces were filtered at 2 kHz and acquired at 10 kHz.
Currents were measured in response to a 1-s pulse of 500 M
acetylcholine (ACh) at a holding potential of 100 mV. Pulse
generation, data collection, and analyses were carried out with
Clampex 10.1 (Molecular Devices, Sunnyvale, CA).
Calcium Flux Assay—SH-SY5Y cells were grown on cover-
slips and treated with 0.15 nM gp120 overnight followed by
incubation on nonsupplement medium with 10 M Fluo4-AM
for 30 min in the dark. Cells were then washed with PBS and
incubated with acini buffer (120 mM NaCl, 4 mM KCl, 1 mM
CaCl2, 1.2 mM KH2PO4,1m M MgSO4,1 5m M HEPES, 0.1%
BSA, 10 mM glucose, pH 7.4) for 3 min at 37 °C in the dark for
de-esterification.Cellswerethenstimulatedwith1mMAChfor
1.5 min while exciting at a wavelength of 488 nm using an
Argon/2 laser. Emission was acquired at 520 nm using a BP
500-550filteronaZeissLSM510confocalmicroscope.Images
wereacquiredinatimeseriesof180framesat0.5-sintervalsfor
9 0sa t4 0  magnification. To calculate the maximal intensity
(Fmax), incubation with 10 M ionomicin in presence of 10 mM
CaCl2 was performed. Ca
2 concentration was determined as
described (27).
Cell Death Assay—SH-SY5Y cells were treated with gp120
(0.15 nM) overnight. Cell death was measured using the APO-
BrdUTUNELAssaykit(Invitrogen)followingthemanufactur-
er’s instructions with slight modifications. All centrifugations
steps were done at 6,000 rpm. In brief, all cells were detached,
centrifuged for 6 min, fixed with 2% paraformaldehyde for 20
min, and centrifuged for 6 min. Cells were then permeabilized
with 70% ethanol for 24 h at 20 °C, centrifuged for 6 min,
resuspended in wash buffer, and centrifuged again. Then, cells
were incubated with labeling solution for 24 h at room temper-
ature, washed with 1 ml of rinse buffer, and centrifuged. This
stepwasfollowedbyincubationwithantibodystainingsolution
f o r1ha troom temperature. After this, cells were washed with
PBS, mounted in glass slides, and visualized with an Axiovert
200M confocal microscope.
Real-timePCR—TotalRNAwasisolatedfromSH-SY5Ycells
or mouse brains using the TRIzol reagent (Invitrogen). The
cDNA synthesis was carried out using 1 g of total RNA with
theiScript
TMcDNASynthesiskit(Bio-Rad)followingtheman-
ufacturer’sinstructions.Real-timePCRexperimentsweredone
using the iQ
TM SYBR
  Green Supermix (Bio-Rad) in a Master-
cycler
  ep realplex Thermal Cycler (Eppendorf, Hauppauge,
NY). The following primer pairs were used: forward, 5-GCT-
CCGGGACTCAACATG-3 and reverse, 5-GGGATTGTAG-
TTCTTGACCAGC-3 for CHRNA7; forward, 5-AGCACCT-
TCAACCCTCA-3 and reverse, 5-AGTCGAGTGGTTTG-
GCT-3 for EGR1; and forward, 5-GCTCTCTGCTCCTCCT-
GTTC-3 and reverse, 5-GACTCCGACCTTCACCTTCC-3
for GAPDH.
Animals—Transgenic mice expressing the HIV-1 coat pro-
tein gp120 under the regulatory control of a modified murine
glial fibrillary acidic protein gene were obtained from a previ-
ouslyestablishedline(Toggasetal.,Ref.49)andhousedinclear
plastic cages, maintained in a temperature- and humidity-con-
trolled room on a 12-h light/dark cycle with food and water
provided ad libitum. Animals from the background strain
B6SJLF were used as control.
Western Blotting—Transgenic and wild-type (WT) mice
were killed by cervical dislocation, and brains were placed on
HIV-associatedNeurocognitiveDisorder
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 ice and dissected to separate the striatum and hippocampus.
Pulverized tissue was transferred to 15-ml tubes containing
cold radioimmune precipitation assay buffer (10 ml/g) supple-
mented with a protease inhibitor mixture. The sample was agi-
tated for 30 s and incubated for1ha t4
°C, shaking. Then, the
sample was centrifuged at 14,000 rpm for 15 min at 4 °C, and
protein in the lysates was quantified with a BCA kit (Pierce).
Samples containing 50 g of total protein were loaded on a
4–20% linear gradient polyacrylamide gel (Bio-Rad), and elec-
trophoresis was done at 100 mV for1ha troom temperature.
Proteins were transferred to a PVDF membrane (Amersham
Biosciences) at 100 mV for 1 h. Nonspecific binding was
blocked with 5% nonfat dry milk in TBS-T (1)f o r1ha troom
temperature. The membrane was then incubated with a poly-
clonalrabbitanti-7-nAChR(1:1,000;Millipore),dilutedin5%
skimmilk,overnightat4 °C,shaking.Threeconsecutivewashes
with TBS-T (5 min each) were done to eliminate excess anti-
body, and the membrane was incubated with an anti-rabbit
antibody conjugated to HRP (1:5,000; Abcam) for1ha troom
temperature.AntibodybindingwasdetectedwiththeECLPlus
Western blotting detection system (Amersham Biosciences)
and developed using BioMax MS film (Kodak).
Cell Culture and Treatment with Gp120, SDF-1,o r
AMD3100—SH-SY5Y cells were grown in DMEM/F12
medium supplemented with 10% FBS and 1% antibiotic/anti-
micotic solution (Sigma-Aldrich) and treated for 24 h. Several
compounds were used at various concentrations: gp120IIIB
(Fitzgerald Industries International, Concord, MA), SDF-1
(EMDChemicals,Inc.,Gibbstown,NJ)at0.3g/ml;AMD3100
(EMDChemicals,Gibbstown,NJ)at1M,wherepretreatment
wascarriedout10minbeforetheadditionofgp120orSDF-1;
and -bgtx (Invitrogen) at 1 M, where pretreatment was car-
ried out 10 min before the addition of gp120 or SDF-1.
RESULTS
Gp120 Increases -Bgtx Binding and Acetylcholine-stimu-
latedCurrentsinSH-SY5YCells—Tostudytheeffectsofgp120
on7-nAChRexpression,SH-SY5Ycellsweretreatedwithdif-
ferent concentrations of gp120. Alexa Fluor 488--bgtx was
used to detect 7-nAChRs. As shown in Fig. 1, A and B, cells
treated with various concentrations of gp120 showed an
increase in -bgtx binding, consistent with higher levels of
7-nAChRs. To determine whether the increase in -bgtx
binding correlates with an increase in functional nAChRs, we
FIGURE 1. Increased -bgtx binding and ACh-stimulated currents in SH-SY5Y cells after treatment with gp120. A, Alexa Fluor 488-conjugated -bgtx
bindingtoSH-SY5Ywasassessedincellstreatedwith0.15,15,150,or1,500nMgp120,orcontrolcells.B,normalizedfluorescenceintensityforcontrolSH-SY5Y
cellswas100.06.0%(n16).Cellstreatedwith0.15,15,150,and1,500nMshowedapercentagefluorescenceintensityof163.526.7%(n12),174.6
10.7%(n13),150.49.1%(n12),and167.526.3%(n17),respectively.C,wholecellrepresentativecurrenttracesrecordedfromcontrolSH-SY5Ycells
orcellstreatedwith0.15,15,150,and1,500nMgp120areshown.Currentswererecordedinresponsetoapplicationofa1m MAChpulseataholdingpotential
of100mV.D,averagedensityforACh-stimulatedcurrentsrecordedfromcontrolSH-SY5Ycellswas18.93.9pA/pF(n15).Forcellstreatedwith0.15,15,
150,and1,500nMgp120,theaveragecurrentdensitywas32.113.1pA/pF(n4),48.58.1pA/pF(n7),41.716.9pA/pF(n7),and44.79.5pA/pF
(n  12), respectively. *, p  0.05.
HIV-associatedNeurocognitiveDisorder
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 measured currents in response to stimulation with 1 mM ACh
using the whole cell configuration of the patch clamp tech-
nique. As shown in Fig. 1, C and D, cells treated with different
concentrations of gp120 presented an increase in whole cell
current density in response to ACh. These results show that
gp120treatmentleadstoanincreaseinfunctional7-nAChRs.
Gp120EffectsAreMediatedbyCXCR4Receptor—Ithasbeen
shown that gp120 activates the chemokine receptor CXCR4,
whichisexpressedinSH-SY5Ycells(10).Wehypothesizedthat
this receptor was involved in the gp120-induced up-regulation
of 7-nAChRs on the basis of findings by Luo et al. (23) and
Criado and del Toro (24), which showed that SDF-1, the
endogenousCXCR4agonist,up-regulatesEgr-1,aknowntran-
scription factor for the 7-nAChR. As shown in Fig. 2A, the
CXCR4 antagonist, AMD3100, prevented the increase in
-bgtx binding observed after treatment with gp120. Pretreat-
ment with AMD3100 also prevented the gp120-induced
increase in ACh-stimulated currents (Fig. 2B). These results
reveal that CXCR4 activation by gp120 is necessary for the
up-regulation of the 7-nAChR. On the basis of these find-
ings, we proceeded to test whether activation of the CXCR4
receptor by its endogenous ligand, SDF-1, would have simi-
lar effects on -bgtx binding and ACh-stimulated currents.
Fig. 2B shows that SDF-1 treatment resulted in increased
-bgtx binding and ACh-stimulated currents, similar to
what was observed after gp120 treatment. The 7-nAChR
up-regulation can be prevented by the MEK inhibitor
PD98059, suggesting that the effect of SDF1 requires activa-
tion of the MAP kinase pathway (supplemental Fig. S2).
Gp120IncreasesACh-stimulatedCalciumMovement—Ofall
the nicotinic receptors, the 7-nAChR has the highest perme-
abilitytoCa
2ions(28,29).Takingthisfactintoconsideration,
we decided to measure the intracellular Ca
2 concentration
after stimulating SH-SY5Y cells with ACh. As shown in Fig. 3,
control cells stimulated with ACh had an increase in intracel-
lular Ca
2 concentration ( [Ca
2]i) that peaked around 100 nM
(supplemental Video S1). This increase in [Ca
2]i can be
blocked by the addition of methyllycaconitine (supplemental
Video S3), a selective antagonist for the 7-nAChR, suggesting
its role in mediating this effect. In contrast, cells treated with
gp120 (0.15 nM) had an increase in [Ca
2]i that peaked at
around 1,100 nM (supplemental Video S2), 11 times more than
the[Ca
2]iobservedincontrolcells.Oncemore,thiseffectcan
beinhibitedbyadditionofMLA(supplementalVideoS4),con-
FIGURE2.CXCR4receptormediatesgp120-inducedup-regulationof7-nAchR.A,AlexaFluor488-conjugated-bgtxbindingtocontrolSH-SY5Ycellsor
cells treated with 1,500 nM gp120, 1,500 nM gp120 plus AMD3100 (0.1 M), SDF-1 (0.3 g/ml), or SDF-1 (0.3 g/ml) plus AMD3100 (0.1 M) was assessed. B,
percentage fluorescence intensity for control SH-SY5Y cells was 100.0  6.5% (n  14). Cells treated with 1,500 nM gp120 showed a percentage fluorescence
intensityof153.913.1%(n12).Thepercentagefluorescenceforcellstreatedwith1,500nMgp120plusAMD3100was90.29.7%(n15).Cellstreated
withSDF-1hadapercentagefluorescenceintensityof207.117.3%(n11).C,representativewholecellcurrenttracesofcontrolSH-SY5Ycells,cellstreated
with 1,500 nM gp120, gp120 plus AMD3100, SDF-1, or SDF-1 plus AMD3100 are shown. D, average current density for control cells was 18.9  3.9 pA/pF (n 
15).Cellstreatedwithgp120,gp120plusAMD3100,SDF-1,andSDF-1plusAMD3100showedanaveragecurrentdensityof44.79.4pA/pF(n12),20.7
5.9 pA/pF (n  9), 58.9  13.1 pA/pF (n  5), and 16.0  4.1 (n  4), respectively. Currents were recorded as described for Fig. 1. *, p  0.05.
HIV-associatedNeurocognitiveDisorder
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 firming the involvement of the 7-nAChR in mediating the
increase in [Ca
2]i.
Gp120-induced Up-regulation of 7-nAChRs Leads to Cell
Death—When considering the effects of the increase in
7-nAChRs for cellular function, it is important to keep in
mindthatlargeincreasesinintracellularCa
2havebeenshown
to induce cell death (30). Moreover, treatment with gp120 has
beenshowntoinducecelldeathinneuroblastomacells(10).To
testthehypothesisthat7-nAChRup-regulationplaysarolein
the gp120-induced cell death observed in SH-SY5Y cells, we
performed TUNEL staining after treatment with gp120 with
and without the addition of -bgtx, an 7-nAChR antagonist.
Fig. 4 shows that antagonizing 7-nAChRs with -bgtx
reduced the percentage of cells undergoing cell death after
treatment with gp120. These data suggest that increased activ-
ity of 7-nAChRs contributes to gp120-induced cell death.
7-nAChR and Egr-1 mRNA Levels Are Up-regulated in
SH-SY5Y Cells Treated with Gp120—The experiments per-
formed in SH-SY5Y cells suggest that CXCR4 activation by
either gp120 or SDF-1 results in increased levels of functional
7-nAChRs. The CXCR4 receptor has been shown to activate
the early growth response protein, Egr-1 (23). Egr-1, binds to
the promoter region of the 7 gene and increases transcription
(24, 31). Real-time PCR on SH-SY5Y cells treated with gp120
fordifferentperiodsoftimeshowedafastandtransientup-reg-
ulationofEgr-1withapeakof8.4-foldincreaseafter30min.To
test whether 7-nAChRs mRNA levels are increased after
treatment with gp120, real-time PCR was performed using
CHRNA7-specific primers. Fig. 5 shows that the transient up-
regulation of Egr-1 was accompanied by an 4-fold increase in
7 mRNA levels that peaked 60 min after gp120 treatment.
Consistently, increased 7-nAChR currents were observed as
early as 1 h after gp120 treatment and persisted for at least 48 h
(supplemental Fig. S1).
7-nAChR mRNA and Protein Levels Are Increased in
Gp120-transgenic Mice—Quantitative RT-PCR and Western
blotting experiments showed that mRNA and protein levels of
7-nAChRsareincreasedintheCNSofgp120-transgenicmice
(Fig. 5). However, the up-regulation of 7-nAChRs was
observed in the striatum, a region affected in HAND patients,
but not in the hippocampus (supplemental Fig. S3). Interest-
ingly,thestriatumexpresseshighlevelsoftheCXCR4receptor
FIGURE 3. Increased Ca
2 mobilization after gp120 treatment. Gp120 exposure that induced up-regulation of the 7-nAChR led to a remarkable Ca
2
mobilizationinSH-SY5Ycells.Ourdatausingconfocalmicroscopysuggestthatneuroblastomacellsexposedtogp120(0.15nM)reachahigher[Ca
2]i(1,179
222.0nM)(B)inresponsetoAChthandocontrolcells(108.69.2nM)(A).TheCa
2mobilizationcanbeblockedbypreincubationwithmethyllycaconitine,an
antagonist of the 7-nAChR in gp120-treated (167.0  48.0 nM) and control (51.7  3.3 nM) cells.
HIV-associatedNeurocognitiveDisorder
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 and,furthermore,theexpressionofthisreceptorisincreasedin
HIV
 patients (32). These findings are in agreement with our
data from SH-SY5Y cells, and previous studies that implicate
the CXCR4 in gp120-induced neurotoxicity (33, 34).
DISCUSSION
We have developed a model for gp120 neurotoxicity, in
which activation of the CXCR4 receptor by gp120 or SDF1
leads to activation of the MAPK pathway, increased EGR1 lev-
els, and up-regulation of 7-nAChRs that triggers cell death
(Fig. 6). This model is supported by data showing that treat-
ment of SH-SY5Y cells with gp120 results in higher expression
of 7-nAChRs, which are highly permeable to Ca
2. Increased
intracellularCa
2canleadtocelldeathandhasbeenassociated
with neuronal death in neurodegenerative diseases (35). Along
these lines, overexpression of 7-nAChRs has been shown to
playaroleinneurologicaldisorders(36).Studieshaveshown
that in neuronal cultures, gp120 can induce an increase in
Ca
2 levels, leading to neuronal injury, an effect that can be
blockedwithmemantine(37).Interestingly,besidesbeingan
antagonist for the NMDA receptor, memantine has been
showntoalsoactasanantagonistof7-nAChRs(38).More-
over,subsequentstudieshaveshowninvolvementofCXCR4
in the neurotoxic effects of gp120 (38). These results suggest
that other proteins, besides the NMDA receptor, contribute
to gp120 neurotoxicity.
TUNEL staining showed that exposure to gp120 increases
cell death in SH-SY5Y cells, consistent with previous studies
(37, 39). Our experiments show that pretreatment with -bgtx
reduced the percentage of cells undergoing cell death after
gp120 treatment. These data suggest that the gp120-induced
up-regulation of functional 7-nAChRs may be detrimental to
neuronsandimplicatesthe7-nAChRasapotentialkeyplayer
in HIV pathogenesis. It is important to mention that desensiti-
zationof7-nAChRsbychronicexposuretodifferentagonists,
such as nicotine, has been associated to receptor up-regulation
and neuroprotection (40, 41). This scenario differs from the
gp120-induced 7-nAChR up-regulation and toxicity in that
the observed gp120 effects involve activation of the CXCR4
receptor. It is conceivable that chronic nicotine exposure leads
to an increase in 7-nAChRs to compensate for the reduced
receptor activity due to desensitization. In contrast, our data
suggest that gp120 activates CXCR4 receptors, leading to an
increase in functional 7-nAChRs without involving desensiti-
zation. Whereas small influxes in Ca
2 associated with tonic
small levels of activation of 7-nAChRs might be neuroprotec-
tive, large influxes of Ca
2 as consequence of receptor up-reg-
ulation appear to be cytotoxic (42, 43).
Many studies have shown that gp120 binding to the CXCR4
or CCR5 receptors elicits intracellular responses that include
theactivationoftheMAPKpathway,transcriptionfactors,and
ion channels (32, 44–46). In the course of HIV infection, the
virus exhibits changes in its tropism: from an R5 variant to an
X4variant(15).BythetimeHIV-1becomescapableofinfecting
cells through the use of the CXCR4, there is an associated CD4
celldeclineanddiseaseprogression(20).Thisrapiddecreasein
CD4cellcountassociatedwithCXCR4tropismcoupleswithan
increased risk of developing HAND (18). This correlates with
the fact that hippocampal and basal ganglia neurons express
CXCR4 but not CCR5, which is present in glial cells (32). Pre-
vious studies have demonstrated that activation of CCR5 can
lead to cell death in the presence of gp120 (51); however, our
experiments show that gp120IIIB as well as SDF-1, both spe-
cific to CXCR4, induce an up-regulation of the 7-nAChR.
Moreover, this effect is abolished by pretreatment with the
CXCR4 antagonist AMD3100, ruling out the contribution of
CCR5 in our experimental setting. These results show that
CXCR4 activation is necessary for the up-regulation of
7-nAChRs, and CXCR4-expressing neurons would be more
susceptible to the effects of HIV infection.
CXCR4 activates the MAPK pathway, and its activation by
SDF-1inducestheup-regulationofEgr-1,atranscriptionfac-
tor capable of stimulating the expression of the 7 gene
(CHRNA7) (23, 24). Our experiments show that treating
SH-SY5YcellswithSDF-1inducedafunctionalup-regulation
of 7-nAChRs, as seen by increased -bgtx binding and larger
ACh-stimulatedwholecellcurrents.Furthermore,quantitative
RT-PCR experiments showed that gp120 and SDF-1 treat-
mentofSH-SY5Ycellsinducedarapidandtransientincreasein
Egr-1mRNAexpressionlevelsconcomitantwithanincreasein
7-nAChRs mRNA expression levels. Together, these results
provideamolecularmechanismastohowthe7-nAChRcould
FIGURE 4. -Bgtx treatment reduces gp120-induced cell death in
SH-SY5Y cells. A, TUNEL staining of control SH-SY5Y cells (top left), cells
treated with 0.15 nM gp120 with or without incubation with 1 M -Bgtx
(middle),orcellstreatedwith1.5nMgp120withorwithoutincubationwith1
M-Bgtx(bottom).B,thepercentofcelldeathincontrolcellswas7.41.8%
(N6),whereascellstreatedwith0.15nMand1.5nMgp120presented19.6
3.5%(N6)and19.21.5%(N4),respectively.Cellstreatedwith0.15nM
gp120-Bgtxor1.5nMgp120-Bgtxpresented10.22.5%(N4)and
7.2  2.6% (N  4) cell death, respectively. *, p-value 0.05.
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 be up-regulated in neurons in the context of an HIV-infected
CNS.
InHAND,thesustainedimmuneresponsecanproduceneu-
ronal injury despite viral control (47). In the brain, viral parti-
cles such as gp120 can cause macrophages and/or astrocytes to
releasevariouscytokinesandchemokines(nitricoxide,TNF-,
IL-1, IL-6, monocyte chemoattractant protein 1), resulting in
further neuronal stress and cell death. Production of IL-1 by
astrocytes leads to an increase in SDF-1 (25). The 7-nAChR
hasbeenshowntocontributetotheregulationofinflammation
in macrophages (the cholinergic anti-inflammatory pathway);
however, the sustained immune response and increased pro-
duction of SDF-1 could cause alterations in 7-nAChR func-
tion. Immune responses depend on the equilibrium between
pro- and anti-inflammatory cytokines, and alterations of this
equilibrium could convert a beneficial inflammatory response
intoapathologicprocess(48).Inthiscontext,gp120andSDF-1
could have synergistic effects, leading to up-regulation of the
7-nAChR and subsequent neuronal death. Interestingly, a
similar up-regulation of 7-nAChR has been observed in
macrophagesderivedfromHIV
donors,
5buttheimplications
of these findings for macrophage function and inflammation
remain to be explored.
5 L. Y. Ballester, C. M. Capó-Vélez, W. F. García-Beltrán, F. M. Ramos, E.
Vázquez-Rosa, R. Ríos, J. R. Mercado, R. I. Meléndez, and J. A. Lasalde-
Dominicci, unpublished data.
FIGURE 6. Proposed mechanism for gp120-induced up-regulation of the
7-nAChR. Activation of CXCR4 by SDF-1 or gp120 causes activation of the
Ras-Raf-MEKpathway.ThisleadstoactivationofEgr-1,aknowntranscription
factor for the 7-nAChR gene (CHRNA7). Activation of Egr-1 leads to an
increase in 7-nAChR mRNA levels.
FIGURE 5. Real-time PCR and Western blot analysis of 7-nAChR on SH-SY5Y and gp120-transgenic mice. A, SH-SY5Y cells were treated with gp120 at
differenttimepoints.Up-regulationof7-nAChRisobservedafterexposuretogp120(n3).B,levelsofEgr-1mRNAincreasedtransientlyinSH-SY5Ycellsafter
gp120treatment(n3).C,increaseinthelevelsof7-nAChRmRNAwasobservedinthestriatumofgp120-transgenicmice(7.550.77,n3)comparedwith
WT(1.00.1,n4)animals.D,Westernblotanalysisofproteinextractsfromstriatumrevealedincreasein7-nAChRproteiningp120-transgenic(TG)mice
compared with WT.
HIV-associatedNeurocognitiveDisorder
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 To validate our results in an in vivo model, we used trans-
genic mice that express HIV-gp120 under the glial fibrillary
acidic protein promoter. HIV-gp120 has been shown to induce
neuropathological changes in mice similar to those seen in
HAND patients (49, 50), making it a suitable model to study
gp120-mediated neurotoxicity. Consistent with the results
frominvitroexperiments,weobservedthat7-nAChRmRNA
andproteinlevelsareincreasedintheCNSofgp120-transgenic
mice. However, the 7-nAChR up-regulation appears to be
restrictedtothestriatum,acomponentofthebasalgangliaand
a region greatly affected in HAND patients (47).
Ourresultsareinagreementwithexperimentsperformedby
Kaul et al. (51) showing that gp120IIIB and SDF-1 are neuro-
toxic only in the presence of the CXCR4 receptor. In these
experiments it was shown that inhibiting p38 prevented the
gp120 and SDF-1 neurotoxicity. Interestingly, it has been
shown that induction of Egr-1 requires p38 activity (52). These
data, in conjunction with our results, suggest the existence of a
neurotoxic pathway in which CXCR4 activation leads to a p38-
dependent Egr-1 induction that increases 7-nAChR expres-
sion levels and causes cell death.
Inconclusion,ourexperimentssuggestthatthe7-nAChRis
a previously unrecognized contributor to HIV neurotoxicity.
DrugsthatantagonizetheCXCR4or7-nAChreceptorsmight
be of therapeutic benefit in the treatment of HAND.
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 ﾠ
Figure S1. Time course of gp120 effects on acetylcholine-stimulated currents in SH-SY5Y 
cells. (A) Whole-cell representative current traces recorded from either control SH-SY5Y cells or 
cells treated with 1500 nM gp120 for 1, 24, or 48 hours. (B) The average current density for control 
SH-SY5Y cells was 19.7 ± 2.8 pA/pF (n = 14). The average current density for cells exposed to 
gp120 for 1, 24, and 48 hours was 31.9 ± 5.5 pA/pF (n = 10), 39.3 ± 8.6 pA/pF (n = 14), and 35.6 ± 
6.9 pA/pF (n = 9), respectively.  Currents were recorded as described for Figure 1. *, p-value < 0.05	 ﾠ
Figure S2. Up-regulation of the α7-nAchR requires activation of MEK. (A) Whole-cell 
representative current traces recorded from SH-SY5Y cells, cells treated with SDF1, or cells treated 
with SDF1 and PD98059.  (B) The average current density for SDF1-treated cells was 107.1       ± 
22.6 pA/pF (n = 12) and was 50.1 ± 13.1 pA/pF (n = 13) for cells treated with SDF1 and SDF1 + 
PD98059.  
Figure S3. Real-time PCR  and Western blot analysis of α7-nAChR in hippocampus of gp120-
transgenic mice.  No difference in α7-nAChR mRNA (A) or protein levels (B) was detected in the 
hippocampus of gp120 transgenic mice as compared with WT (n = 3).     
 
Supplemental videos. Ca
2+ mobilization in SH-SY5Y cells. HIV-gp120 treated SH-SY5Y cells 
stimulated with ACh (VS2) present larger calcium mobilization when compared to control cells 
(VS1).  The specific α7-nAchR antagonist MLA inhibits Ca
2+ mobilization in response to ACh 
(VS3 and VS4), showing that the change in intracellular [Ca
2+] requires this receptor. 
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